Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Purpose
This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving rituximab or mosunetuzumab works better in treating patients with follicular lymphoma with a low tumor burden.
Conditions
- Classic Follicular Lymphoma
- Follicular Lymphoma With Unusual Cytological Features
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Criteria
Inclusion Criteria:
- Participants must have a histologically confirmed diagnosis of classic follicular
lymphoma (cFL). cFL was previously categorized as grade 1-3A per World Health
Organization (WHO)-HAEM4R, but grading of classic follicular lymphoma (FL) is no
longer mandatory.
- NOTE: Participants with follicular lymphoma with uncommon features (uFL) are
eligible, including FL with diffuse growth pattern (dFL). Diagnosis is as per
local pathology. Lymphoma fluorescence in situ hybridization (FISH) is not
required. Molecular testing is not required.
- Participants must not have follicular lymphoma with "blastoid" or "large centrocyte"
cytological features, or follicular large B-cell lymphoma (FLBL) (previously
categorized as follicular lymphoma grade 3B)
- Participants must have low-tumor burden follicular lymphoma defined as:
- Nodal or extra-nodal tumor mass with diameter less than 7 cm in its greater
diameter
- Involvement of no more than 3 nodal or extra nodal sites with diameter greater
than 3 cm.
- Absence of B symptoms
- No symptomatic splenomegaly
- No compression syndrome (ureteral, orbital, gastrointestinal)
- No pleural or peritoneal serous effusion related to follicular lymphoma
Participants must have Ann Arbor stage II, III, or IV follicular lymphoma.
Participants with stage I disease may be included if they do not wish to
undergo radiation or are not candidates for radiation
- Participants must either be experiencing distress due to their disease or would
prefer active management of their disease rather than a watch and wait approach
- Participants must have staging imaging performed within 49 days prior to
registration, as follows. PET-CT baseline scans are preferred. If a baseline PET-CT
scan cannot be obtained, CT scans of the chest, abdomen, and pelvis, along with a
bone marrow biopsy, are acceptable. If CT scans are used for staging at baseline, a
CT scan of the neck is recommended. All measurable dominant lesions must be assessed
within 49 days prior to registration. Tests to assess non-measurable disease must be
performed within 49 days prior to registration. All disease must be assessed and
documented on the Baseline Tumor Assessment Form.
- NOTE: if the initial evaluation is insufficient to detect measurable disease,
treating investigators may obtain a CT scan with contrast
- Participants must have bi-dimensionally measurable disease (at least one lesion with
longest diameter > 1.5 cm)
- Participants must not have had prior systemic therapy for follicular lymphoma.
Radiation therapy for a previous diagnosis of early-stage follicular lymphoma is
allowed
- Participant must be ≥ 18 years of age at the time of registration
- Participant must have Zubrod performance status of 0-2
- Participant must have a complete medical history and physical exam within 28 days
prior to registration
- Leukocytes ≥ 3 x 10^3/uL (within 28 days prior to registration)
- Hemoglobin > 9.0 g/dL (within 28 days prior to registration)
- Absolute neutrophil count ≥ 1.5 x 10^3/uL (within 28 days prior to registration)
- Platelets ≥ 100 x 10^3/uL (within 28 days prior to registration)
- Total bilirubin ≤ 2 x institutional upper limit of normal (ULN) unless history of
Gilbert's disease. Participants with history of Gilbert's disease must have total
bilirubin ≤ 5 x institutional ULN (within 28 days prior to registration)
- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 3 × institutional
ULN (within 28 days prior to registration)
- Lactate dehydrogenase (LDH) < institutional ULN (within 28 days prior to
registration)
- Participants must have a calculated creatinine clearance ≥ 30 mL/min using the
following Cockcroft-Gault Formula. This specimen must have been collected and
processed within 28 days prior to registration
- Participants must not have an active or uncontrolled infection before initiation of
study treatment in the opinion of the treating investigators
- Participants must not have uncontrolled diabetes within 14 days prior to
registration in the opinion of the treating investigators
- Participants must not have uncontrolled blood pressure and hypertension within 14
days prior to registration in the opinion of the treating investigators
- Participants with known human immunodeficiency virus (HIV)-infection must be on
effective anti-retroviral therapy at registration and have undetectable viral load
test on the most recent test results obtained within 6 months prior to registration
- Participants with evidence of chronic hepatitis B virus (HBV) infection must have
undetectable HBV viral load while on suppressive therapy on the most recent test
results obtained within 6 months prior to registration, if indicated. Participants
with a positive total hepatitis (Hep) B core antibody and negative hepatitis B virus
surface antigen (HBsAg) at screening are at high risk for reactivation and should
receive prophylactic antivirals (e.g., entecavir) before and throughout the
treatment
- Participants must not have active autoimmune disease requiring systemic therapy
- Participants must not have had undergone organ transplants requiring ongoing
systemic immunosuppressive therapy
- Participants with a history of hepatitis C virus (HCV) infection must have been
treated and cured. Participants currently being treated for HCV infection must have
undetectable HCV viral load test on the most recent test results obtained within 6
months prior to registration, if indicated
- Participants must not have known chronic active Epstein Barr Virus infection
(CAEBV); testing in asymptomatic participants is not required
- Participants must not have a positive test result for COVID-19 within seven (7) days
prior to registration
- Participants must not have a prior or concurrent malignancy whose natural history or
treatment (in the opinion of the treating physician) has the potential to interfere
with the safety or efficacy assessment of the investigational regimen
- Participants must not have a history of confirmed progressive multifocal
leukoencephalopathy (PML)
- Participants must not have received allogeneic stem cell transplantation
- Participants must not have a history of macrophage activation syndrome (MAS) or
hemophagocytic lymphohistiocytosis (HLH)
- Participants with known history or current symptoms of cardiac disease, or history
of treatment with cardiotoxic agents, must have a clinical risk assessment of
cardiac function using the New York Heart Association Functional Classification.
Participant must not have significant cardiovascular disease such as class III or IV
cardiac disease, myocardial infarction within 6 months prior to registration.
Participants with unstable arrhythmias, or unstable angina, should be excluded
- Participants must not be pregnant or nursing (nursing includes breast milk fed to an
infant by any means, including from the breast, milk expressed by hand, or pumped).
Individuals who are of reproductive potential must have agreed to use an effective
contraceptive method with details provided as a part of the consent process. A
person who has had menses at any time in the preceding 12 consecutive months or who
has semen likely to contain sperm is considered to be of "reproductive potential."
In addition to routine contraceptive methods, "effective contraception" also
includes refraining from sexual activity that might result in pregnancy and surgery
intended to prevent pregnancy (or with a side-effect of pregnancy prevention)
including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion,
and vasectomy with testing showing no sperm in the semen
- Participants must be offered the opportunity to participate in specimen banking.
With participant consent, specimens must be collected and submitted via the
Southwest Oncology Group (SWOG) Specimen Tracking System
- NOTE: As a part of the Oncology Patient Enrollment Network (OPEN) registration
process the treating institution's identity is provided in order to ensure that the
current (within 365 days) date of institutional review board approval for this study
has been entered in the system.
- Participants must be informed of the investigational nature of this study and
must sign and give informed consent in accordance with institutional and
federal guidelines
- For participants with impaired decision-making capabilities, legally authorized
representatives may sign and give informed consent on behalf of study
participants in accordance with applicable federal, local, and Central
Institutional Review Board (CIRB) regulations
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Arm I (Rituximab, rituximab and hyaluronidase) |
Patients receive rituximab IV on day 1 of cycle 1 and receive rituximab and hyaluronidase SC on days 8, 15 and 22 of cycle 1 and SC on day 1 of subsequent cycles. Cycles repeat every 56 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and/or PET/CT and blood sample collection on study and during follow up. |
|
|
Experimental Arm II (Mosunetuzumab) |
Patients receive mosunetuzumab SC on days 1, 8 and 15 of cycle 1 and on day 1 of subsequent cycles. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and/or PET/CT and blood sample collection on study and during follow up. |
|
Recruiting Locations
Birmingham, Alabama 35233
Phoenix, Arizona 85054
Site Public Contact
855-776-0015
Tucson, Arizona 85719
Tucson, Arizona 85719
Little Rock, Arkansas 72205
Site Public Contact
501-686-8274
Beverly Hills, California 90211
Duarte, California 91010
Irvine, California 92612
Irvine, California 92618
Site Public Contact
877-467-3411
Lancaster, California 93534
Long Beach, California 90813
Site Public Contact
877-467-3411
Los Angeles, California 90048
Site Public Contact
310-423-8965
Orange, California 92868
South Pasadena, California 91030
Upland, California 91786
Newark, Delaware 19713
Newark, Delaware 19713
Aventura, Florida 33180
Site Public Contact
954-461-2180
Coral Gables, Florida 33146
Site Public Contact
305-243-2647
Coral Springs, Florida 33065
Site Public Contact
305-243-2647
Deerfield Beach, Florida 33442
Site Public Contact
305-243-2647
Doral, Florida 33166
Hollywood, Florida 33021
Site Public Contact
305-243-2647
Jacksonville, Florida 32224-9980
Site Public Contact
855-776-0015
Miami, Florida 33136
Site Public Contact
305-243-2647
Miami, Florida 33176
Site Public Contact
305-243-2647
Plantation, Florida 33324
Site Public Contact
305-243-2647
Atlanta, Georgia 30308
Site Public Contact
888-946-7447
Atlanta, Georgia 30322
Site Public Contact
404-778-1868
Atlanta, Georgia 30342
Site Public Contact
404-851-7115
Augusta, Georgia 30912
Boise, Idaho 83706
Caldwell, Idaho 83605
Coeur d'Alene, Idaho 83814
Nampa, Idaho 83687
Post Falls, Idaho 83854
Sandpoint, Idaho 83864
Bloomington, Illinois 61704
Carthage, Illinois 62321
Chicago, Illinois 60637
Danville, Illinois 61832
Decatur, Illinois 62526
Decatur, Illinois 62526
Dixon, Illinois 61021
Site Public Contact
815-285-7800
Effingham, Illinois 62401
Effingham, Illinois 62401
Eureka, Illinois 61530
Galesburg, Illinois 61401
Kewanee, Illinois 61443
Macomb, Illinois 61455
Mattoon, Illinois 61938
New Lenox, Illinois 60451
O'Fallon, Illinois 62269
Orland Park, Illinois 60462
Ottawa, Illinois 61350
Pekin, Illinois 61554
Peoria, Illinois 61615
Peru, Illinois 61354
Princeton, Illinois 61356
Shiloh, Illinois 62269
Springfield, Illinois 62702
Site Public Contact
217-545-7929
Springfield, Illinois 62702
Site Public Contact
800-444-7541
Springfield, Illinois 62781
Urbana, Illinois 61801
Washington, Illinois 61571
Crown Point, Indiana 46307
Ames, Iowa 50010
Site Public Contact
515-956-4132
Ames, Iowa 50010
Bettendorf, Iowa 52722
Boone, Iowa 50036
Site Public Contact
515-956-4132
Cedar Rapids, Iowa 52403
Site Public Contact
319-365-4673
Cedar Rapids, Iowa 52403
Site Public Contact
319-363-2690
Fort Dodge, Iowa 50501
Site Public Contact
515-956-4132
Iowa City, Iowa 52242
Site Public Contact
800-237-1225
Jefferson, Iowa 50129
Site Public Contact
515-956-4132
Marshalltown, Iowa 50158
Site Public Contact
515-956-4132
Hays, Kansas 67601
Site Public Contact
785-623-5774
Kansas City, Kansas 66160
Lawrence, Kansas 66044
Olathe, Kansas 66061
Overland Park, Kansas 66210
Salina, Kansas 67401
Topeka, Kansas 66606
Site Public Contact
785-295-8000
Westwood, Kansas 66205
Baton Rouge, Louisiana 70805
Baton Rouge, Louisiana 70808
Bethesda, Maryland 20889-5600
Site Public Contact
301-319-2100
Battle Creek, Michigan 49017
Brighton, Michigan 48114
Canton, Michigan 48188
Chelsea, Michigan 48118
Detroit, Michigan 48201
Detroit, Michigan 48202
Farmington Hills, Michigan 48334
Flint, Michigan 48503
Flint, Michigan 48503
Flint, Michigan 48503
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
Lansing, Michigan 48912
Livonia, Michigan 48154
Muskegon, Michigan 49444
Niles, Michigan 49120
Site Public Contact
616-391-1230
Norton Shores, Michigan 49444
Pontiac, Michigan 48341
Reed City, Michigan 49677
Saint Joseph, Michigan 49085
Saint Joseph, Michigan 49085
Traverse City, Michigan 49684
Wyoming, Michigan 49519
Ypsilanti, Michigan 48197
Brainerd, Minnesota 56401
Burnsville, Minnesota 55337
Coon Rapids, Minnesota 55433
Deer River, Minnesota 56636
Duluth, Minnesota 55805
Edina, Minnesota 55435
Hibbing, Minnesota 55746
Site Public Contact
218-786-3308
Minneapolis, Minnesota 55407
Rochester, Minnesota 55905
Site Public Contact
855-776-0015
Saint Louis Park, Minnesota 55416
Saint Paul, Minnesota 55101
Saint Paul, Minnesota 55102
Sandstone, Minnesota 55072
Virginia, Minnesota 55792
Cape Girardeau, Missouri 63703
Creve Coeur, Missouri 63141
Farmington, Missouri 63640
Site Public Contact
314-996-5569
Kansas City, Missouri 64108
Site Public Contact
816-404-4375
Kansas City, Missouri 64154
Lee's Summit, Missouri 64064
Saint Louis, Missouri 63110
Saint Louis, Missouri 63129
Saint Louis, Missouri 63131
Site Public Contact
314-996-5569
Saint Louis, Missouri 63136
Saint Peters, Missouri 63376
Sainte Genevieve, Missouri 63670
Site Public Contact
314-996-5569
Sullivan, Missouri 63080
Site Public Contact
314-996-5569
Sunset Hills, Missouri 63127
Site Public Contact
314-996-5569
Anaconda, Montana 59711
Billings, Montana 59101
Bozeman, Montana 59715
Great Falls, Montana 59405
Missoula, Montana 59804
Henderson, Nevada 89052
Las Vegas, Nevada 89102
Las Vegas, Nevada 89148
Lebanon, New Hampshire 03756
Long Branch, New Jersey 07740
New Brunswick, New Jersey 08903
Site Public Contact
732-235-7356
Rochester, New York 14642
Site Public Contact
585-275-5830
Webster, New York 14580
Charlotte, North Carolina 28203
Site Public Contact
800-804-9376
Charlotte, North Carolina 28204
Charlotte, North Carolina 28210
Site Public Contact
980-442-2000
Charlotte, North Carolina 28211
Site Public Contact
980-442-2000
Charlotte, North Carolina 28262
Site Public Contact
800-804-9376
Clemmons, North Carolina 27012
Site Public Contact
888-716-9259
Clinton, North Carolina 28328
Concord, North Carolina 28025
Site Public Contact
800-804-9376
Durham, North Carolina 27710
Site Public Contact
888-275-3853
Goldsboro, North Carolina 27534
Jacksonville, North Carolina 28546
Winston-Salem, North Carolina 27103
Winston-Salem, North Carolina 27157
Site Public Contact
336-713-6771
Fargo, North Dakota 58103
Columbus, Ohio 43210
Oklahoma City, Oklahoma 73104
Ontario, Oregon 97914
Portland, Oregon 97213
Portland, Oregon 97225
Portland, Oregon 97227
Portland, Oregon 97239
Providence, Rhode Island 02903
Site Public Contact
401-444-1488
Charleston, South Carolina 29425
Houston, Texas 77030
Salt Lake City, Utah 84112
Charlottesville, Virginia 22908
Richmond, Virginia 23235
Richmond, Virginia 23298
Charleston, West Virginia 25304
Site Public Contact
304-388-9944
Ashland, Wisconsin 54806
La Crosse, Wisconsin 54601
Milwaukee, Wisconsin 53226
Site Public Contact
414-805-3666
Mukwonago, Wisconsin 53149
Oconomowoc, Wisconsin 53066
Site Public Contact
262-928-7878
Waukesha, Wisconsin 53188
Site Public Contact
262-928-7632
Waukesha, Wisconsin 53188
More Details
- NCT ID
- NCT06337318
- Status
- Recruiting
- Sponsor
- National Cancer Institute (NCI)
Detailed Description
PRIMARY OBJECTIVES: I. To compare the 3-year milestone progression free survival (PFS) probabilities in participants with previously untreated, low tumor burden follicular lymphoma randomized to the rituximab arm versus the mosunetuzumab arm. II. To compare progression free survival (PFS) in participants with previously untreated, low tumor burden follicular lymphoma randomized to the rituximab arm versus the mosunetuzumab arm. SECONDARY OBJECTIVES: I. To compare overall survival (OS) between participants randomized to rituximab versus mosunetuzumab. II. To compare overall response rates at the Week 40 assessment between participants randomized to rituximab versus mosunetuzumab. III. To compare event free survival (EFS) between participants randomized to rituximab versus mosunetuzumab. IV. To compare the frequency and severity of toxicities between participants randomized to rituximab versus mosunetuzumab. V. To compare the restricted chance of longer PFS (2-6 years) between participants randomized to rituximab versus mosunetuzumab. BANKING OBJECTIVE: I. To bank specimens for future correlative studies. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive rituximab intravenously (IV) on day 1 of cycle 1 and receive rituximab and hyaluronidase subcutaneously (SC) on days 8, 15 and 22 of cycle 1 and SC on day 1 of subsequent cycles. Cycles repeat every 56 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) scan and/or positron emission tomography (PET)/CT and blood sample collection on study and during follow up. ARM II: Patients receive mosunetuzumab SC on days 1, 8 and 15 of cycle 1 and on day 1 of subsequent cycles. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and/or PET/CT and blood sample collection on study and during follow up. After completion of study treatment, patients are followed up every 6 months for 5 years and then yearly for a total of 10 years.